Wednesday May 15 | MediLexicon
Drug Improves Memory In Mice With Alzheimer's Disease
A novel drug candidate, J147, is able to reverse memory deficits and improve several aspects of brain function in mice with advanced symptoms of Alzheimer's disease , finds research in BioMed Central's open access journal Alzheimer's Research & Therapy.
Ranbaxy Pays $500 Million Fine for Selling Bad Batches of Generic Medicines
Ranbaxy, a subsidiary of Japanese pharmaceutical company Daiichi Sankyo, has paid a $500 million fine and pled guilty to selling adulterated drugs manufactured in India .
Improving memory in Alzheimer's Disease mice
A novel drug candidate, J147, is able to reverse memory deficits and improve several aspects of brain function in mice with advanced symptoms of Alzheimer's disease , finds research in BioMed Central's open access journal Alzheimer's Research & Therapy .
Anavex invited to submit funding application for Phase 2a trial of ANAVEX 2-73
Anavex Life Sciences Corp. today announced that it has been invited to submit a full grant application to the Alzheimer's Drug Discovery Foundation for a Phase 2a trial of ANAVEX 2-73. Since 1998, the ADDF has granted more than $51 million in venture philanthropy funding to projects with potential viability in the market.
Medication adherence and tolerability of Alzheimer's disease...
The class of acetylcholinesterase inhibitors , including donepezil, rivastigmine, and galantamine, have similar efficacy profiles in patients with mild to moderate Alzheimer's disease .
The impact of Medicare prescription drug coverage on the use of antidementia drugs
Cholinesterase inhibitors and memantine are prescribed to slow the progression dementia.